



ESME Ovarian Cancer

Publications

Health Data & partnership Department

Publications in peer-review journals

1. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Uncancer database.
De Nonnville A, Zemmour C, Franck S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye MA, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R.
Gyn Oncol. 2021 Oct;163(1):64-71 <https://doi.org/10.1016/j.ygyno.2021.07.019>
2. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
Thomas QD, Boussere A, Classe JM, Pomel C, Costa H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, De la Motte Rouge T, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F.
Gynecol Oncol. 2022 Aug;S0090-8258 <https://doi.org/10.1016/j.ygyno.2022.08.005>
3. Real-world data on newly diagnosed BRCA-mutated high-grade epithelial ovarian cancers: the French national multicenter ESME database.
Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De la Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F.
Cancers. 2022 Aug;14(16):4040 <https://doi.org/10.3390/cancers14164040>

Publications in peer-review journals

4. Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.
Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M.
Int J Gynecol Cancer. 2023 Jan <https://doi.org/10.1136/ijgc-2022-003993>
5. PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network
Rippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, Gladieff L, Pautier P, Frénel JS, Costaz H, Lebreton C, Pomel C, Colombo PÉ, Marchal F, Guillemet C, de la Motte Rouge T, Eberst L, Bosquet L, Deluche E, Sabatier R
The Oncologist. 2025 May;30(5) <https://doi.org/10.1093/oncolo/oyaf075>
6. Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database
Chator C, Chevrier M, Frenel JS, Guyon F, Sabatier R, Pomel C, De la Motte Rouge T, Pautier P, Gladieff L, Follana P, Colombo PE, Petit T, Guillemet C, Marchal F, Narducci F, Fumet JD, Rodrigues M, Bosquet L, Rouzier R, Ray-Coquard I
Gynecologic Oncology 2025 Oct; 201:17-25 <https://doi.org/10.1016/j.ygyno.2025.08.004>

Publications in peer-review journals

7. Surgical Approach and Maintenance Therapy in Advanced Low-Grade Serous Ovarian Cancer: Insights from the French ESME Database
Papazyan T, Martin E, Pautier P, Guerin-Charbonnel C, Rowinski E, Lecuru F, Joly Lobbedez F, De La Motte Rouge T, Guillemet C, Costaz H, Sabatier R, Barranger E, Colombo; PE, Marchal F, Pomel C, Savoye AM, Bosquet L, Ray-Coquard I, Gladieff L, Loaec C, Frenel JS
Int J Gynecol Cancer. 2025 [In Press]